Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

30.20 +0.70 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Earnings Outlook For Collegium Pharmaceutical
Via Benzinga
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
Highlights 2022 environmental, social and governance achievements 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Analyst Sees This 'Specialty Pharma' Stock Stuck Until Prescription Trends Improve
Via Benzinga
Recap: Collegium Pharmaceutical Q1 Earnings
Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! 
Via InvestorPlace
Why Collegium Pharmaceutical's Shares Are Trading Higher Today
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Provides 2023 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Third Quarter 2022 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
7 Micro-Cap Stocks to Take a Chance on Now
Despite (or because of) their size, some micro-cap stocks, have good value and are overlooked and should be considered by investors. 
Via InvestorPlace
A Preview Of Collegium Pharmaceutical's Earnings
Collegium Pharmaceutical (NASDAQ:COLL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Analyst Ratings For Collegium Pharmaceutical
Over the past 3 months, 4 analysts have published their opinion on Collegium Pharmaceutical (NASDAQ:COLL) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
JP Morgan raised Ralph Lauren Corporation (NYSE: RL) price target from $137 to $142. Ralph Lauren shares rose 1.2% to $124.00 in pre-market trading. 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences... 
Via Benzinga
BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today
Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. 
Via InvestorPlace
32 Stocks Moving In Monday's Mid-Day Session
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares jumped 51.9% to $5.53. Collegium Pharmaceutical will acquire BioDelivery Sciences International at $5.60... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback